US FDA Warns Supplement Own Labeler About Reliance On Manufacturer For Compliance
Executive Summary
Revival Products’ GMP deficiencies concerned work and training of its quality control staff, including failing to document review and approval for release of any packaged and labeled supplement for distribution and destroying returned products without review.
You may also be interested in...
Supplement GMP Warnings Followed After US FDA Restarted Facility Inspections
GMP warnings to firms making supplement firms marketed in US have been rare since FDA temporarily suspended on-site inspections with onset of COVID-19 pandemic. But GMP problems surfaced after agency resumed inspections last July.
Own-Labeler Lesson, Ingredient-Testing Lapse Noted Again In FDA Warnings
Sportron International "cannot contract out its ultimate responsibility to ensure that the dietary supplement it places into commerce" is compliant, and Absonutrix failed "to conduct at least one appropriate test or examination to verify the identity of a dietary ingredient," say FDA warning letters listing some of the most frequently noted problems found in GMP and labeling inspections.
ForMor Challenges FDA On Own-Label Supplement GMP Stance
ForMor contests a warning letter from FDA stating that as an own-label distributor, the firm is subject to both packager and labeler GMP requirements. The firm says it is only a “holder” of finished products and FDA bases its warning on the GMP rule preamble, not the actual rule.